New horizons in cancer therapy: Manipulating tumour metabolism

Biomedical Research

Volumn 23, Issue SPEC. ISSUE, 2012, Pages 17-23

  Yeluri, Sashidhar ^a   Madhok, Brijesh M ^a   Jayne, David G ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Dichloroacetate; Glycolysis; Hypoxia inducible factor; Pyruvate dehydrogenase kinase; Warburg effect

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; BEVACIZUMAB; DICHLOROACETIC ACID; DIGOXIN; ERLOTINIB; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; PYRUVATE DEHYDROGENASE KINASE 2; PYRUVATE DEHYDROGENASE KINASE 3; PYRUVATE DEHYDROGENASE KINASE 4; REACTIVE OXYGEN METABOLITE; TOPOTECAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CELL; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL ACTIVITY; CELL CYCLE ARREST; CHEMOSENSITIZATION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; GLIOBLASTOMA; GLIOMA; GLYCOLYSIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; METABOLIC REGULATION; METASTASIS; MITOCHONDRIAL RESPIRATION; NONHUMAN; OVARY CANCER; OXIDATIVE PHOSPHORYLATION; PHYSIOLOGICAL PROCESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; WARBURG PHENOMENON;

EID: 84857184925     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Warburg O. On the origin of cancer cells. Science 1956; 123 (3191): 309-314.
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4(11): 891-9.
3. Gatenby RA, Smallbone K, Maini PK et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 2007; 97 (5): 646-653.
4. Milosevic M, Fyles A, Hedley D et al. The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004; 14 (3): 249-258.
5. Dewhirst MW, Tso CY, Oliver R et al. Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 1989; 17 (1): 91-99.
6. Shah-Yukich AA, Nelson AC. Characterization of solid tumor microvasculature: a three-dimensional analysis using the polymer casting technique. Lab Invest 1988; 58 (2): 236-244.
7. Wu M, Neilson A, Swift AL et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 2007; 292 (1): C125-C136.
8. Bi X, Lin Q, Foo TW et al. Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol Cell Proteomics 2006; 5 (6): 1119-1130.
9. Iyer NV, Kotch LE, Agani F et al. Cellular and developmental control of O2 homeostasis by hypoxiainducible factor 1 alpha. Genes Dev 1998; 12 (2): 149-162.
10. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998; 8 (5): 588-594.
11. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11 (3): 293-299.
12. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2 (1): 38-47.
13. O'Donnell JL, Joyce MR, Shannon AM et al. Oncological implications of hypoxia inducible factor- 1alpha (HIF-1alpha) expression. Cancer Treat Rev 2006; 32 (6): 407-416.
14. Kondoh H. Cellular life span and the Warburg effect. Exp Cell Res 2008; 314 (9): 1923-1928.
15. Papandreou I, Cairns RA, Fontana L et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3 (3): 187-197.
16. Lu CW, Lin SC, Chen KF et al. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008; 283 (42): 28106-28114.
17. Kim JW, Tchernyshyov I, Semenza GL et al. HIF-1- mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3 (3): 177-185.
18. Koukourakis MI, Giatromanolaki A, Sivridis E et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003; 89 (5): 877-885.
19. Koukourakis MI, Giatromanolaki A, Simopoulos C et al. Lactate dehydrogenase 5 (LDH5) relates to upregulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 2005; 22(1): 25-30.
20. Rajaganeshan R, Prasad R, Guillou PJ et al. Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases. Eur J Surg Oncol 2009.
21. Rajaganeshan R, Prasad R, Guillou PJ et al. The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer. Int J Colorectal Dis 2008; 23 (11): 1049-1055.
22. Aebersold DM, Burri P, Beer KT et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61(7): 2911-2916.
23. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59(22): 5830-5835.
24. Talks KL, Turley H, Gatter KC et al. The expression and distribution of the hypoxia-inducible factors HIF- 1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157 (2): 411-421.
25. Zagzag D, Zhong H, Scalzitti JM et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000; 88 (11): 2606-2618.
26. Bachtiary B, Schindl M, Potter R et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003; 9 (6): 2234-2240.
27. Schindl M, Schoppmann SF, Samonigg H et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph nodepositive breast cancer. Clin Cancer Res 2002; 8 (6): 1831-1837.
28. Birner P, Schindl M, Obermair A et al. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7 (6): 1661-1668.
29. Birner P, Gatterbauer B, Oberhuber G et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001; 92 (1): 165-171.
30. Plas DR, Thompson CB. Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab 2002; 13 (2): 75-78.
31. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988; 4: 155-181.
32. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99 (7): 989-994.
33. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001; 2 (1): 67-71.
34. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66(18): 8927-30.
35. Yeluri S, Madhok B, Prasad KR et al. Cancer's craving for sugar: an opportunity for clinical exploitation. J Cancer Res Clin Oncol 2009; 135 (7): 867-877.
36. Madhok BM, Yeluri S, Perry SL et al. Targeting Glucose Metabolism: An Emerging Concept for Anticancer Therapy. Am J Clin Oncol 2010.
37. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006; 18 (6): 598-608.
38. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic require ments of cell proliferation. Science 2009; 324 (5930): 1029-1033.
39. Thorn CC, Freeman TC, Scott N et al. Laser microdissection expression profiling of marginal edges of colorectal tumours reveals evidence of increased lactate metabolism in the aggressive phenotype. Gut 2009; 58 (3): 404-412.
40. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13 (6): 472-482.
41. Pelicano H, Martin DS, Xu RH et al. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25 (34): 4633-4646.
42. Scatena R, Bottoni P, Pontoglio A et al. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs 2008; 17 (10): 1533-1545.
43. De LM, Lorusso V, Latorre A et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 2001; 37 (3): 364-368.
44. Amadori D, Frassineti GL, De MA et al. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Breast Cancer Res Treat 1998; 49 (3): 209-217.
45. Pacini P, Rinaldini M, Algeri R et al. FEC (5- fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. Eur J Cancer 2000; 36 (8): 966-975.
46. Berruti A, Bitossi R, Gorzegno G et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol 2002; 20 (20): 4150-4159.
47. Papaldo P, Lopez M, Cortesi E et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 2003; 21 (18): 3462-3468.
48. Kamlah F, Eul BG, Li S et al. Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther 2009; 16 (3): 195-205.
49. Stoeltzing O, McCarty MF, Wey JS et al. Role of hypoxia- inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96 (12): 946-956.
50. Kizaka-Kondoh S, Itasaka S, Zeng L et al. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 2009; 15 (10): 3433-3441.
51. Rapisarda A, Zalek J, Hollingshead M et al. Scheduledependent inhibition of hypoxia-inducible factor- 1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004; 64 (19): 6845-6848.
52. Rapisarda A, Hollingshead M, Uranchimeg B et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009; 8 (7): 1867-77.
53. Kummar S, Raffeld M, Juwara L et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res 2011; 17 (15): 5123-5131.
54. Zhang H, Qian DZ, Tan YS et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008; 105 (50): 19579-1986.
55. Rowles J, Scherer SW, Xi T et al. Cloning and characterization of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human. J Biol Chem 1996; 271 (37): 22376-22382.
56. Gudi R, Bowker-Kinley MM, Kedishvili NY et al. Diversity of the pyruvate dehydrogenase kinase gene family in humans. J Biol Chem 1995; 270 (48): 28989-28994
57. Popov KM, Kedishvili NY, Zhao Y et al. Molecular cloning of the p45 subunit of pyruvate dehydrogenase kinase. J Biol Chem 1994; 269 (47): 29720-29724.
58. Bowker-Kinley MM, Davis WI, Wu P et al. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998; 329 (Pt 1): 191-196.
59. Wu P, Sato J, Zhao Y et al. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J 1998; 329 (Pt 1): 197-201.
60. Pilegaard H, Neufer PD. Transcriptional regulation of pyruvate dehydrogenase kinase 4 in skeletal muscle during and after exercise. Proc Nutr Soc 2004; 63(2): 221-226.
61. Sugden MC, Holness MJ. Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2 (2): 151-165.
62. Wigfield SM, Winter SC, Giatromanolaki A et al. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer 2008; 98 (12): 1975-1984.
63. Koukourakis MI, Giatromanolaki A, Sivridis E et al. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor- associated stroma. Neoplasia 2005; 7 (1): 1-6.
64. Lu CW, Lin SC, Chien CW et al. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol 2011; 179 (3): 1405-1414.
65. Koukourakis MI, Pitiakoudis M, Giatromanolaki A et al. Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Sci 2006; 97 (10): 1056-1060.
66. McFate T, Mohyeldin A, Lu H et al. Pyruvate dehydrogenase complex activity controls metabolic and malig nant phenotype in cancer cells. J Biol Chem 2008; 283 (33): 22700-22708.
67. Bonnet S, Archer SL, lalunis-Turner J et al. A mitochondria- K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11 (1): 37-51.
68. Stacpoole PW. Lactic acidosis. Endocrinol Metab Clin North Am 1993; 22 (2): 221-245.
69. Stacpoole PW. Lactic acidosis and other mitochondrial disorders. Metabolism 1997; 46 (3): 306-321.
70. Stacpoole PW, Lorenz AC, Thomas RG et al. Dichloroacetate in the treatment of lactic acidosis. Ann Intern Med 1988; 108 (1): 58-63.
71. Stacpoole PW, Nagaraja NV, Hutson AD. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003; 43 (7): 683-691.
72. Stacpoole PW, Moore GW, Kornhauser DM. Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. N Engl J Med 1978; 298 (10): 526-530.
73. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism 1989; 38 (11): 1124-1144.
74. Moore GW, Swift LL, Rabinowitz D et al. Reduction of serum cholesterol in two patients with homozygous familial hypercholesterolemia by dichloroacetate. Atherosclerosis 1979; 33 (3): 285-293.
75. Taniguchi M, Wilson C, Hunter CA et al. Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak. Am J Physiol Heart Circ Physiol 2001; 280 (4): H1762-H1769.
76. Wambolt RB, Lopaschuk GD, Brownsey RW et al. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol 2000; 36 (4): 1378-1385.
77. Platz TA, Wilson JS, Kline JA et al. The beneficial effects of dichloroacetate in acute limb ischemia. Mil Med 2007; 172 (6): 628-633.
78. Whitehouse S, Randle PJ. Activation of pyruvate dehydrogenase in perfused rat heart by dichloroacetate (Short Communication). Biochem J 1973; 134 (2): 651-653.
79. Wong JY, Huggins GS, Debidda M et al. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 2008; 109 (3): 394-402.
80. Sun RC, Fadia M, Dahlstrom JE et al. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 2010; 120 (1): 253-260.
81. Vella S, Conti M, Tasso R et al. Dichloroacetate (DCA) inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells. Int J Cancer 2011.
82. Madhok BM, Yeluri S, Perry SL et al. Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer 2010; 102 (12): 1746-1752.
83. Tong J, Xie G, He J et al. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol 2011; 2011: 740564.
84. Fiebiger W, Olszewski U, Ulsperger E et al. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol 2011; 13 (1): 43-49.
85. Xie J, Wang BS, Yu DH et al. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. Int J Oncol 2011; 38 (2): 409-417.
86. Cao W, Yacoub S, Shiverick KT et al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 2008; 68 (11): 1223-1231.
87. Khan A. Use of oral dichloroacetate for palliation of leg pain arising from metastatic poorly differentiated carcinoma: a case report. J Palliat Med 2011; 14 (8): 973-7.
88. Flavin DF. Non-Hodgkin's Lymphoma Reversal with Dichloroacetate. J Oncol 2010; 2010.